BioCryst’s BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema

BioCryst’s BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema

May 24, 2018 EMA Grants Orphan Designation UK MHRA Grants Promising Innovative Medicine Designation RESEARCH TRIANGLE PARK, N.C., May 24, 2018 (GLOBE NEWSWIRE) —¬†BioCryst Pharmaceuticals, Inc.¬†(NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases,